![Lawrence Kenyon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lawrence Kenyon
Finanzdirektor/CFO bei
OUTLOOK THERAPEUTICS, INC.
Vermögen: 4 150 $ am 31.05.2026
Profil
Currently, Lawrence A. Kenyon is CFO, Secretary, Treasurer, Director, and Executive VP at Outlook Therapeutics, Inc. since 2015.
Formerly, served as President, CEO, CFO, and Secretary at Tamir Biotechnology, Inc. in 2013; Director at Tamir Biotechnology, Inc. in 2009; Chief Financial Officer and Executive Vice President at Endo Generics Holdings, Inc. from 2009 to 2010; Chief Financial Officer, Secretary, and EVP at NeoPharm, Inc. from 2000 to 2006; Chief Financial Officer at Par Pharmaceutical, Inc. from 2009 to 2010; and Chief Operating and Financial Officer at Arno Therapeutics, Inc. from 2014 to 2015.
Education includes an undergraduate degree from the University of Wisconsin, conferred in 1987.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.05.2026 | 5’685 ( 0% ) | 4 150 $ | 31.05.2026 |
Aktive Positionen von Lawrence Kenyon
| Unternehmen | Position | Beginn |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Finanzdirektor/CFO | 18.06.2018 |
Ehemalige bekannte Positionen von Lawrence Kenyon
| Unternehmen | Position | Ende |
|---|---|---|
| ARNO THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.09.2015 |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Vorstandsvorsitzender | 31.03.2013 |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Finanzdirektor/CFO | 01.07.2010 |
| PAR PHARMACEUTICAL COMPANIES, INC. | Finanzdirektor/CFO | 04.06.2010 |
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Finanzdirektor/CFO | 01.02.2009 |
Ausbildung von Lawrence Kenyon
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
92
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Health Technology |
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Operates as a holding company with interests in developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States | Health Technology |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology Provides drug research, development and commercialization services | Health Technology |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Health Technology |
Arno Therapeutics, Inc.
 Arno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs | Health Technology |
Outlook Therapeutics, Inc.
 Outlook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bevacizumab therapeutic products | Health Technology |
